Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation
- PMID: 23049460
- PMCID: PMC3448245
Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation
Abstract
In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their heterogeneity, recommendations for the immunization of immunocompromised patients may not be universally applicable. The safety of many commonly used vaccines has not been established in immunocompromised children. In addition, no large-scale vaccine studies have evaluated the clinical outcome of disease prevention in this population. All killed vaccines are generally safe, while live vaccines may be administered to immunocompromised children in select circumstances, depending on the degree of altered immunocompetence and the underlying primary condition. Healthcare providers should be knowledgeable about the indications, contraindications, and precautions for vaccine administration in immunocompromised patients. To protect immunocompromised patients, all family, household contacts, and healthcare workers should also be immunized with all routinely recommended vaccines. Pediatricians play a crucial role in identifying and effectively communicating the risks and benefits of vaccines to immunocompromised patients and their parents.
Keywords: Cancer; hematopoietic stem cell transplantation; immunization; immunocompromised children; vaccines.
Conflict of interest statement
Similar articles
-
[IMMUNIZATIONS IN IMMUNOCOMPROMISED HOSTS--PRINCIPLES AND UPDATED RECOMMENDATIONS].Harefuah. 2015 Dec;154(12):786-90, 804, 803. Harefuah. 2015. PMID: 26897782 Review. Hebrew.
-
[Vaccination].Klin Padiatr. 2001 Sep;213 Suppl 1:A77-83. doi: 10.1055/s-2001-17503. Klin Padiatr. 2001. PMID: 11577366 Review. German.
-
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16. MMWR Recomm Rep. 2003. PMID: 12710832
-
Smallpox vaccination and adverse reactions. Guidance for clinicians.MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28. MMWR Recomm Rep. 2003. PMID: 12617510
-
A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients.Clin Ther. 2017 Aug;39(8):1581-1598. doi: 10.1016/j.clinthera.2017.07.005. Epub 2017 Jul 24. Clin Ther. 2017. PMID: 28751095 Review.
Cited by
-
Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura.BMC Infect Dis. 2022 Jul 28;22(1):657. doi: 10.1186/s12879-022-07647-1. BMC Infect Dis. 2022. PMID: 35902837 Free PMC article.
-
Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification.Front Aging. 2021 Jul 19;2:708788. doi: 10.3389/fragi.2021.708788. eCollection 2021. Front Aging. 2021. PMID: 35822014 Free PMC article. Review.
-
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.BMC Infect Dis. 2021 Jan 11;21(1):46. doi: 10.1186/s12879-020-05656-6. BMC Infect Dis. 2021. PMID: 33430796 Free PMC article.
-
Revaccination in Pediatric Oncology Patients: One Center Experience.Eurasian J Med. 2021 Feb;53(1):5-8. doi: 10.5152/eurasianjmed.2020.20047. Eurasian J Med. 2021. PMID: 33716522 Free PMC article.
-
Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis.Mol Cell Pediatr. 2018 Jan 19;5(1):1. doi: 10.1186/s40348-018-0079-0. Mol Cell Pediatr. 2018. PMID: 29352427 Free PMC article.
References
-
- Roush SW, Murphy TV. Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007 Nov 14;298(18):2155–2163. - PubMed
-
- Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine. 2010 Apr 26;28(19):3278–3284. Epub 2010 Mar 10. - PubMed
-
- Ruggiero A, Battista A, Coccia P, Attinà G, Riccardi R. How to manage vaccinations in children with cancer. Pediatr Blood Cancer. 2011 Dec 15;57(7):1104–1108. Epub 2011 Sep 23. - PubMed
-
- Allen UD. Immunizations for children with cancer. Pediatr Blood Cancer. 2007 Dec;49((7 Suppl)):1102–1108. - PubMed
-
- Abzug MJ. Vaccination in the immunocompromised child: a probe of immune reconstitution. Pediatr Infect Dis J. 2009 Mar;28(3):233–236. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous